Andrew J. Schwab sold $140k of SKYE
director, owner at Skye Bioscience, Inc.. 375,840 shares at an average of $0.37, traded Aug 18, 2026, filed Aug 20, 2026.
Score components
- +15RoleDirector
- +11Trade size$140k at market
- +10Share of holdings soldSold 26% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001598549-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -45,090 | $0.38 | $17k | 1,411,974 | Aug 20, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -1,830 | $0.38 | $695 | 55,663 | Aug 20, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures VII, L.P. | -253,080 | $0.38 | $96k | 7,914,126 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -10,255 | $0.35 | $3,589 | 1,401,719 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -409 | $0.35 | $143 | 55,254 | Aug 20, 2026 |
| Aug 19, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures VII, L.P. | -57,476 | $0.35 | $20k | 7,856,650 | Aug 20, 2026 |
| Aug 20, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -1,159 | $0.32 | $371 | 1,400,560 | Aug 20, 2026 |
| Aug 20, 2026 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -46 | $0.32 | $15 | 55,208 | Aug 20, 2026 |
| Aug 20, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures VII, L.P. | -6,495 | $0.32 | $2,078 | 7,850,155 | Aug 20, 2026 |
Related signals
Other insiders at Skye Bioscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $240k 148,079 shares | -104% | |
| 56Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $240k 148,079 shares | -104% | |
| 33Weak | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $65k 33,892 shares | -19% | |
| 36Weak | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $65k 33,892 shares | -19% | |
| 41Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $140k 375,840 shares | -26% | |
| 47Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $801k 231,405 shares | -14% | |
| 50Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $801k 231,405 shares | -14% | |
| 45Moderate | Skye Bioscience, Inc. | Tuan Tu Diep Chief Development Officer | $98k 19,574 shares | -19% | |
| 54Moderate | Skye Bioscience, Inc. | Kaitlyn Arsenault Chief Financial Officer | $217k 43,396 shares | -21% | |
| 61Notable | Skye Bioscience, Inc. | Punit Dhillon Chief Executive Officer | $414k 82,910 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.